Antibiotic prophylaxis for spontaneous bacterial peritonitis;Antibioprophylaxie de l'infection du liquide d'ascite

Gastroenterologie Clinique et Biologique

Volumn 22, Issue 3, 1998, Pages 301-304

  Grangé, Jean Didier ^a   Amiot, Xavier ^a  

^a HÔPITAL TENON   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CIPROFLOXACIN; COTRIMOXAZOLE; NORFLOXACIN;

ANTIBIOTIC PROPHYLAXIS; ANTIBIOTIC THERAPY; ASCITES; BACTERIAL PERITONITIS; DRUG EFFICACY; GRAM NEGATIVE INFECTION; HUMAN; LIVER CIRRHOSIS; REVIEW; STAPHYLOCOCCUS INFECTION; STREPTOCOCCUS INFECTION;

ANTIBIOTIC PROPHYLAXIS; ASCITIC FLUID; BACTERIAL INFECTIONS; CLINICAL TRIALS; HUMANS; QUINOLONES; RISK FACTORS;

EID: 0031918736     PISSN: 03998320     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (33)

1. Grangé JD, Amiot X. La prophylaxie des complications infectieuses par décontamination bactérienne digestive sélective chez les malades atteints de cirrhose. Gastroenterol Clin Biol 1992;16:692-700.
2. Gilbert JA, Kamath PS. Spontaneous bacterial peritonitis. An update. Mayo Clin Proc 1995;70:365-70.
3. Runyon B, Squier S, Borzio M. Translocation of gut bacteria in rats with cirrhosis to mesenteric lymph nodes partially explains the pathogenesis of spontaneous bacterial peritonitis. J Hepatol 1994;21:792-6.
4. Deitch EA, Winterton J, Li M, Berg R. The gut as a portal of entry for bacteremia. Role of protein malnutrition. Ann Surg 1987;205:681-92.
5. 3 in cirrhotic ascites predisposes to spontaneous bacterial peritonitis. J Hepatol 1988;6:80-4.
6. Graham DY, Smith JL. The course of patients after variceal hemorrhage. Gastroenterology 1981;80:800-9.
7. Carr FD, Loegering DI. Reticuloendothelial system function and humoral factor deficiency following acute hemorrhage. Can J Physiol Pharmacol 1978;56:299-303.
8. Rimola A, Bory F, Terés J, Pérez-Ayuso RM, Arroyo V, Rodés J. Oral, nonabsorbable antibiotics prevent infection in cirrhotics with gastrointestinal haemorrhage. Hepatology 1985;5:463-7.
9. Schembre D, Bjorkman DJ. Post-sclerotherapy bacterial peritonitis. Am J Gastroenterol 1991;86:481-5.
10. Tito L, Rimola A, Gines P, Llach J, Arroyo V, Rodes J. Recurrence of spontaneous bacterial peritonitis in cirrhosis. Hepatology 1988;8:27-31.
11. Gines P, Rimola A, Planas R, Vargas V, Marco F, Almela M, et al. Norfloxacin prevents spontaneous bacterial peritonitis recurrence in cirrhosis: results of a double-blind, placebo-controlled trial. Hepatology 1990;12:716-24.
12. Bercoff E, Durrbach A, Manchon ND, Duranton Y, Senant J, Lecomte N, et al. La concentration des protides dans l'ascite permet-elle de prévoir la survenue d'une infection du liquide d'ascite ? Gastroenterol Clin Biol 1987;11:636-8.
13. Llach J, Rimola A, Navasa M, Ginès P, Salmeròn JM, Ginès A, et al. Incidence and predictive factors of first episode of spontaneous bacterial peritonitis in cirrhosis with ascites. Relevance of ascitic fluid protein concentration. Hepatology 1992;16:724-7.
14. Andreu M, Sola R, Sitges-Serra A, Alia C, Gallen M, Vila C, et al. Risk factors for spontaneous bacterial peritonitis in cirrhotic patients with ascites. Gastroenlerology 1993;104:1133-8.
15. Casafon T, Morencos F, De Las Herras-Castano G, Martin-Ramos L, Lopez-Arias MJ, Ledesma F, et al. Small bowel bacterial peritonitis overgrowth in patients with alcoholic cirrhosis. Dig Dis Sci 1995;40:1252-6.
16. Soriano G, Guarner C, Teixido M, Such J, Barrios J, Enriquez J, et al. Selective intestinal decontamination prevents spontaneous bacterial peritonitis. Gastroenterology 1991;100:477-81.
17. Singh N, Gayowski T, Yu VL, Wagener M. Trimethoprim-sulfamethoxazole for the prevention of spontaneous bacterial peritonitis in cirrhosis: a randomized trial. Ann Intern Med 1995;122:595-8.
18. Rolachon A, Cordier L, Bacq Y, Nousbaum JB, Franza A, Paris JC, et al. Ciprofloxacin and long-term prevention of spontaneous bacterial peritonitis: results of a prospective controlled trial. Hepatology 1995;22:1171-4.
19. Grangé JD, Roulot D, Pelletier G, Pariente A, Denis J, Ink O, et al. Primary prophylaxis of bacterial infections with norfloxacin in cirrhotic patients with ascites: a prospective, randomized trial (abstract). Gastroenterology 1994;106:A901.
20. King A, Warren C, Shannon K, Phillips I. In vitro antimicrobial activity of norfloxacin (MK-0366). Antimicrob Agents Chemother 1982;21:604-7.
21. Raz R, Boger S. Long-term prophylaxis with norfloxacin versus nitrofurantoin in women with recurrent urinary tract infection. Antimicrob Agents Chemother 1991;35:1241-2.
22. Altman C, Grangé JD, Amiot X, Pelletier G, Lacaine F, Bodin F, et al. Survival after a first episode of spontaneous bacterial peritonitis. Prognosis of potential candidates for orthotopic liver transplantation. J Gastroenterol Hepatol 1995;10:47-50.
23. Soriano G, Guarner C, Tomas A, Villanueva C, Torras X, Gonzalez D, et al. Norfloxacin prevents bacterial infection in cirrhotics with gastrointestinal haemorrhage. Gastroenterology 1992;103:1267-72.
24. Biaise M, Pateron D, Trinchet JC, Levacher S, Beaugrand M, Pourriat JL. Systemic antibiotic therapy prevents bacterial infection in cirrhotic patients with gastro-intestinal hemorrhage. Hepatology 1994;20:34-8.
25. Pauwels A, Mostefa-Kara N, Debenes B, Degoutte E, Lévy VG. Systemic antibiotic prophylaxis after gastro-intestinal hemorrhage in cirrhotic patients with a high risk of infection. Hepatology 1996;24:802-6.
26. Novella MT, Gana J, Soriano G, Andreu M, Ortiz J, Guarner C, et al. Continuous vs intermittent (nosocomial) prophylaxis of the first episode of spontaneous bacterial peritonitis in cirrhotic patients. Final results (abstract). J Hepatol 1994;21 (suppl 1):S46.
27. Bernard B, Grangé JD, Nguyen Khac E, Amiot X, Opolon P, Poynard T. Antibiotic prophylaxis (AbP) for the prevention of bacterial infections in cirrhotic patients with ascites: a metaanalysis (abstract). Hepatology 1996;24:444A.
28. Acar JF, Golstein FW. Trends in bacterial resistances to fluoroquinolones. Clin Infect Dis 1997;24 (suppl 1):S67-73.
29. Truong QC, Ouabdesselam S, Hooper DC, Moreau NJ, Soussy CJ. Sequencial mutations of gyr-A in Escherichia coli associated with quinolone therapy. J Antimicrob Chemother 1995;36:1055-9.
30. Tankovic J, Mahjoubi F, Courvalin P, Duval J, Leclercq R. Development of fluoroquinolone resistance in Enterococcus fœcalis and role of mutation in the DNA gyrase gyr-A gene. Antimicrob Agents Chemother 1996;40:2558-61.
31. Dupeyron C, Mangeney N, Sedrati L, Campillo F, Fouet P, Leluan G. Rapid emergence of quinolone resistance in cirrhotic patients treated with norfloxacin to prevent spontaneous bacterial peritonitis. Antimicrob Agents Chemother 1994;38:340-4.
32. Kalinsky E, Lahmek P, Amiot X, Vergez P, Bodin F, Grangé JD. Conséquences cliniques et bactériologiques de l'utilisation d'une décontamination bactérienne digestive chez les malades atteints de cirrhose (résumé). Gastroenterol Clin Biol 1996;20:818.
33. Llovet JM, Rodriguez-Iglesias P, Moitinho E, Planas R, Bataller R, Navasa M, et al. Spontaneous bacterial peritonitis in patients with cirrhosis undergoing selective intestinal decontamination. A retrospective study of 229 spontaneous bacterial peritonitis episodes. J Hepatol 1997;26:88-95.